drugset / Trial / NCT02442648
B-Cell Targeted Carfilzomib Desensitization
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to provide a preliminary evaluation of the safety and potential efficacy of carfilzomib in reducing HLA antibody levels in highly sensitized kidney transplant candidates.
Timeline
- Start
- 2014-12
- Primary completion
- 2021-06
- Completion
- 2021-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
Indications
No indication recorded.